Sirnaomics Ltd (HKG: 2257) has announced the commencement of a single-center, randomized, double-blind, placebo-controlled, sequence grouping Phase I clinical study for its factor Xl-targeted RNAi drug, STP122G. The US-based trial is designed to assess the safety, tolerability, and pharmacokinetics of the drug in healthy subjects initially, before expanding to its therapeutic applications.
Understanding Factor Xl and Its Role in Coagulation
Factor Xl is an enzyme predominantly produced by hepatocytes in the liver and plays a crucial role in the body’s blood clotting cascade. STP122G is capable of inhibiting Factor Xl, impacting the internal coagulation pathway without affecting the external pathway or bleeding times, which presents a potential advantage in targeted anticoagulation therapies.
Development and Potential Applications of STP122G
STP122G was developed using Sirnaomics’ proprietary GalNAc RNAi delivery platform technology. The drug is currently under development to treat conditions such as atrial fibrillation, pulmonary embolism, and deep vein thrombosis. STP122G is also considered to have the potential to target multiple diseases that require anticoagulation, including atrial fibrillation, pulmonary embolism, deep vein thrombosis (DVT), and deep venous thrombosis prophylaxis for surgical procedures.
The Significance of the Trial
The initiation of this Phase I clinical study marks a significant step forward for Sirnaomics in advancing its RNAi therapeutics platform. The trial will provide valuable data on the safety and pharmacokinetics of STP122G, which could lead to a new generation of targeted treatments for various thrombotic disorders with fewer bleeding risks.-Fineline Info & Tech
